Gan & Lee Insulin Glargine Target Type (2) Evaluating Research

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 567 participants.

Also called NCT03371108

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 567 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03371108
Other papers using this trial's data
  • Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study Diabetes, obesity & metabolism, 2024-06 DOI, PubMed 38558508

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03371108. Randomized; no masking; primary purpose treatment. Start 2017-10-31 (actual); primary completion 2019-04-17 (actual). Results posted on 2022-03-23.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Gan & Lee Insulin Glargine Target Type (2) Evaluating Research
Acronym
GLITTER 2
Condition
Diabetes Mellitus, Type 2
Intervention (Biological)
Gan & Lee Insulin Glargine Injection
Intervention (Biological)
Lantus®
Lead sponsor
Gan and Lee Pharmaceuticals, USA (class: industry)

Record details

Record id
cardio:ct-nct03371108
Content hash
324ee12561a71a18a677417feeee2849684438c3eba1640d914e98b03681db1f